Over a week ago | ||||
Conference/Events
|
SNN Network to hold a virtual event »
04:55 01/07/21 01/0704:55 01/07/2104:55
CTSDF
Converge Technology
EQ Inc
Equillium
Lexagene Holdings
mCloud Technologies
EnWave
B. Riley Financial
Thunderbird Entertainment
Delta 9 Cannabis
Voyager Digital
SNN Network Canada… SNN Network Canada Virtual Event to be held on January 6-7.Webcast Link ShowHide Related Items >><<
| |||
Conference/Events
|
SNN Network to hold a virtual event »
09:45 01/06/21 01/0609:45 01/06/2109:45
CTSDF
Converge Technology
EQ Inc
Equillium
Lexagene Holdings
mCloud Technologies
EnWave
B. Riley Financial
Thunderbird Entertainment
Delta 9 Cannabis
Voyager Digital
SNN Network Canada… SNN Network Canada Virtual Event to be held on January 6-7.Webcast Link ShowHide Related Items >><<
|
Over a month ago | ||||
Hot Stocks
|
Equillium appoints Dolca Thomas as CMO, EVP, R&D »
08:13 12/21/20 12/2108:13 12/21/2008:13
EQ
Equillium
Equillium announced the… Equillium announced the appointment of Dolca Thomas, M.D., as its executive vice president of research and development and chief medical officer. Dr. Thomas joins Equillium from Principia Biopharma where she was chief medical officer focused on developing treatments for immune-mediated diseases. ShowHide Related Items >><<
| |||
Hot Stocks
|
Equillium presents translational data on itolizumab »
08:41 12/07/20 12/0708:41 12/07/2008:41
EQ
Equillium
Equillium presented data… Equillium presented data over the weekend demonstrating the impact of itolizumab on effector T cell function in graft-versus-host disease. The data was presented virtually at the 2020 American Society of Hematology Annual Meeting and Exposition being held December 5-8, 2020. GVHD is a severe multisystem complication that frequently occurs after hematopoietic stem cell transplantation when there is an upregulation of activated proinflammatory effector T cells resulting in the transplanted immune system attacking and damaging host tissues. There are currently no approved therapies to treat acute GVHD in the first-line setting. The CD6-ALCAM pathway promotes effector T cell activation, proliferation and trafficking, playing a central role in the autoimmune and inflammatory process. Itolizumab is an anti-CD6 monoclonal antibody that has been shown to potentially modulate T cell activity in GVHD. The study described in the oral presentation titled, "Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab", characterized CD6 expression levels and demonstrated the suppressive effect of itolizumab on the activity of CD4 and CD8 T cells from transplant patients with acute GVHD. Additional data presented in a poster reveals itolizumab's direct impact on activated Th1 and Th17 effector T cells shown through decreases of activation markers, cytokine release and CD6 surface expression. ShowHide Related Items >><<
| |||
Conference/Events
|
Equillium to host virtual analyst day »
09:02 12/04/20 12/0409:02 12/04/2009:02
EQ
Equillium
Virtual Analyst Day to be… Virtual Analyst Day to be held on December 4 at 9:30 am. Webcast Link ShowHide Related Items >><<
|
Recommendations
|
Equillium price target lowered to $12 from $22 at H.C. Wainwright »
06:15 11/30/20 11/3006:15 11/30/2006:15
EQ
Equillium
H.C. Wainwright analyst… H.C. Wainwright analyst Raghuram Selvaraju lowered the firm's price target on Equillium to $12 from $22 and reiterates a Buy rating on the shares after the company elected to place the proposed pivotal program to assess itolizumab in COVID-19 on hold. The analyst believes Equillium's decision may have been premature because long-term safety and durability of immunity data for the late-stage COVID-19 vaccines has not yet been generated, but appreciates the company's decision to "act conservatively and cautiously." ShowHide Related Items >><<
|
Hot Stocks
|
Equillium not initiating EQUINOX Phase 3 trial of itolizumab 'at this time' »
08:04 11/25/20 11/2508:04 11/25/2008:04
EQ
Equillium
Equillium announced that… Equillium announced that due to the rapidly evolving COVID-19 treatment landscape, the company will not initiate the EQUINOX Phase 3 clinical trial to evaluate itolizumab in hospitalized COVID-19 patients at this time. "Based on a thorough review of recent updates regarding the efficacy of new potential vaccines and other treatment options, we have made the strategic decision not to initiate our EQUINOX Phase 3 trial as previously planned. We are continuing to assess the rapidly evolving clinical and commercial landscape related to this pandemic and may consider other options to evaluate itolizumab in COVID-19 patients, including government research initiatives," said Bruce Steel, CEO of Equillium. "While this is a difficult decision given the current high rates of infection and significant unmet medical need, we believe it is prudent given the recent positive advancements by our biopharma colleagues to combat this serious pandemic. We greatly appreciate the support and effort of our trial investigators, clinical trial sites, and our Equillium team who played a vital role in preparing for the EQUINOX study, especially during this challenging time. Based on recent positive itolizumab interim clinical data in acute graft-versus-host disease we plan to prioritize our resources on expanding and accelerating this program, as well as advancing our lupus / lupus nephritis and uncontrolled asthma studies. We look forward to providing additional pipeline updates at our Analyst Day on Friday, December 4." ShowHide Related Items >><<
|
On The Fly
|
Fly Intel: After-Hours Movers »
19:06 11/10/20 11/1019:06 11/10/2019:06
FUBO
FuboTV
Myomo
1Life Healthcare
A-Mark Precious Metals
Brooks Automation
Sanmina
Lyft
Equillium
Alcon
Covetrus
Osmotica Pharmaceuticals
Amdocs
Five Prime
eGain
Model N
Grocery Outlet
Datadog
Purple Innovation
Eastman Kodak
Health Catalyst
Rocket Companies
Aurora Cannabis
Viela Bio
Check out this evening's… ShowHide Related Items >><<
|
Earnings
|
Equillium reports Q3 EPS (31c), consensus (40c) »
17:32 11/10/20 11/1017:32 11/10/2017:32
EQ
Equillium
Equillium held cash, cash… Equillium held cash, cash equivalents and short-term investments totaling $90.5M at September 30, compared to $53.1M at December 31, 2019. The increase in cash was driven by $53.8 million in total net proceeds raised from equity financings in 2020 through September 30. "We continue to make significant progress towards our goal of bringing itolizumab to patients suffering from a range of severe immuno-inflammatory disorders," said Bruce Steel, chief executive officer of Equillium. "We are well positioned to continue advancing our core trials including the Phase 1b EQUATE trial in acute graft-versus-host disease (aGVHD) where we recently reported positive response rates across the first three dose cohorts, as well as our Phase 1b EQUIP and EQUALISE trials in uncontrolled asthma and lupus nephritis, respectively. In parallel, we are poised to initiate the global Phase 3 EQUINOX trial of itolizumab in hospitalized COVID-19 patients during this quarter. We look forward to sharing additional updates at our upcoming Analyst Day in December." ShowHide Related Items >><<
|
Hot Stocks
|
Equillium announces interim data of itolizumab in aGVHD »
08:37 11/06/20 11/0608:37 11/06/2008:37
EQ
Equillium
Equillium announced… Equillium announced positive interim data from the third cohort of the Phase 1b open label, dose escalation study of itolizumab in the first-line treatment of acute graft-versus-host disease. The EQUATE trial is evaluating itolizumab in severe aGVHD patients concomitant with standard of care, which is typically comprised of high dose corticosteroids, as no other therapeutics are currently approved for this indication. Equillium anticipates reporting topline data across all cohorts from the Phase 1b portion of the EQUATE trial during the first half of 2021 and is accelerating plans for further development of itolizumab in graft-versus-host disease. In the EQUATE trial, the overall response rate across the first three dose cohorts was 80%, and seven of eight patients responding achieved a complete response and one patient achieved a very good partial response by Day 29. Responses observed have been rapid, with most patients achieving a CR within the first 15 days, and durable as patients in the first two cohorts have maintained responses through Day 57. To date, adverse events reported with the EQUATE trial have been consistent with the safety profile previously reported for itolizumab and those common in the aGVHD patient population. In review of the totality of safety, efficacy and pharmacodynamic data, the independent data monitoring committee has recommended to expand cohort 3 and proceed forward with enrollment. Equillium has received fast track designation from the FDA for the treatment of itolizumab in patients with aGVHD and orphan drug designations from the FDA for both the prevention and treatment of aGVHD. Equillium plans to provide additional updates on the program at its upcoming analyst day on December 4, 2020. ShowHide Related Items >><<
|